4DMedical Ltd (ASX: 4DX) shares are falling again on Wednesday, with the high-growth stock extending losses despite no new update.
At the time of writing, the 4DMedical share price is down a sizeable 9.34% to $4.27.
That follows a 5.23% drop yesterday and leaves the stock down more than 20% over the past week.
There has been no announcement to explain the move, which points to broader forces at play.
Let’s take a closer look.
Selling builds after massive run
The recent pullback comes after an extraordinary run for the stock.
4DMedical shares are still up more than 1,300% over the past 12 months, even after this week’s decline. The company’s market capitalisation sits around $2.5 billion, and it remains in the S&P/ASX 200 Index (ASX: XJO).
That surge was driven by growing interest in its lung imaging platform, alongside regulatory wins and commercial progress in the United States.
But when a stock moves that far, that fast, it tends to attract a lot of short-term interest.
Day traders often pile in during the sharp rally. But when momentum fades, they can exit just as quickly to lock in profits.
And that can amplify the downside, especially when buying support is limited.
Tech sector weakness adds pressure
The broader backdrop is not helping.
The S&P/ASX All Technology Index (ASX: XIJ) is down 4.18% over the past week and has fallen roughly 20% over the past 12 months.
This shows that the selling is not limited to one stock.
Growth shares have been under pressure as investors rotate away from higher-valuation companies, which has been noticeable over the last few sessions.
The ASX 200 Index has also been drifting lower. It is down about 2.93% over the past week and is trading around 8,687 points today.
Valuation and expectations in focus
4DMedical is still in its growth phase.
It is building out its commercial footprint and pushing for wider adoption of its imaging technology. That includes contracts, regulatory approvals, and hospital rollouts.
The trade-off is that earnings remain limited. The company is not profitable yet, and that could take time as it continues to scale.
That leaves the share price closely tied to future expectations.
Foolish Takeaway
This week’s pullback shows how quickly sentiment can shift with high-growth stocks.
4DMedical has clear potential, and its recent run shows how strong the upside can be. But it is still not profitable, which adds risk at current levels.
Personally, I would rather back a more established name like Pro Medicus Ltd (ASX: PME), which is already delivering consistent earnings.
4DMedical may have upside, but it comes with higher volatility and risk.
The post Why this ASX healthcare high-flyer just dropped another 9% today appeared first on The Motley Fool Australia.
Should you invest $1,000 in 4DMedical right now?
Before you buy 4DMedical shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and 4DMedical wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 20 Feb 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- The ASX’s hottest shares just stumbled â warning sign?
- Here are the top 10 ASX 200 shares today
- 6 ASX 200 shares downgraded by brokers this week
- Here are the top 10 ASX 200 shares today
- What are experts saying about these red hot ASX 200 shares?
Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.